Theratechnologies Inc. (THTX)
| Market Cap | 115.42M |
| Revenue (ttm) | 88.67M |
| Net Income (ttm) | -3.71M |
| Shares Out | 45.98M |
| EPS (ttm) | -0.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 771,918 |
| Open | 2.580 |
| Previous Close | 2.570 |
| Day's Range | 2.515 - 2.650 |
| 52-Week Range | 1.080 - 3.130 |
| Beta | 1.50 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Apr 9, 2025 |
About THTX
Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its product pipeline includes tesamorelin... [Read more]
Financial Performance
In 2024, Theratechnologies's revenue was $85.87 million, an increase of 5.02% compared to the previous year's $81.76 million. Losses were -$8.31 million, -65.33% less than in 2023.
Financial StatementsNews
Theratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 Offer
Theratechnologies is likely to accept Future Pak's $255 million offer, presenting a 39%-78% premium over current share prices, despite non-binding risks. The company's HIV franchise, led by EGRIFTA SV...
Theratechnologies Provides Update on Sale Process
MONTREAL, April 15, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that ...
Soleus Capital Issues Letter to The Board of Theratechnologies
GREENWICH, Conn.--(BUSINESS WIRE)--Soleus Capital Management, L.P. (“Soleus Capital”), a healthcare investment firm which owns in excess of 10% of the stock of Theratechnologies Inc. (NASDAQ: THTX) (t...
Theratechnologies Responds to Future Pak's Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company
MONTREAL, April 11, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, wishes to address its...
Future Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total Value
WIXOM, Mich.--(BUSINESS WIRE)--Future Pak, LLC (“Future Pak”) today announced that it has submitted two formal proposals since January to acquire all outstanding shares of common stock of Theratechnol...
Theratechnologies Inc. (THTX) Q1 2025 Earnings Call Transcript
Theratechnologies Inc. (NASDAQ:THTX) Q1 2025 Earnings Conference Call April 9, 2025 8:30 AM ET Company Participants Joanne Choi - Senior Director, Investor Relations Paul Levesque - President and Chi...
Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements
MONTREAL, April 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today reported busine...
Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update
MONTREAL, April 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced the C...
Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy
New, improved formulation set to replace EGRIFTA SV® MONTREAL, March 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-s...
Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI
Results show similar levels of virus undetectability in patients on ibalizumab-containing regimens as in controls, despite greater baseline severity of HIV
Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV
MONTREAL, March 12, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today presented data ...
Theratechnologies Inc. (THTX) Q4 2024 Earnings Call Transcript
Theratechnologies Inc. (NASDAQ:THTX) Q4 2024 Earnings Conference Call February 26, 2024 8:30 AM ET Company Participants Joanne Choi - Senior Director, Investor Relations Paul Levesque - President & C...
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024
MONTREAL, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercializati...
Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
MONTREAL, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercializati...
Theratechnologies Resumes Distribution of EGRIFTA SV®
MONTREAL, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercializati...
Theratechnologies Provides Update on EGRIFTA SV® Supply
MONTREAL, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...
Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
MONTREAL, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA
MONTREAL, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer
No dose-limiting toxicities reported in two different weekly doses in heavily pre-treated patients Preliminary evidence of dose response includes significant tumor shrinkage and one patient with compl...
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada
Addition of investigational RNA-targeted medicines build upon Theratechnologies' foundational HIV portfolio Submissions to Health Canada planned for 2025 MONTREAL, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Th...
Theratechnologies Announces Resumed Production of EGRIFTA SV®
MONTREAL, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...
Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec
MONTREAL, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...
Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review
Resubmission addresses questions raised in January 2024 Complete Response Letter F8 formulation intended to replace EGRIFTA SV ® with simplified dosing for the treatment of excess abdominal fat in adu...
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
MONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and commercializa...
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance
Baseline Data Show More Frequent Selection of Ibalizumab in Patients with Lower CD4 Counts and Higher Viral Loads, Compared to Other Regimens Baseline Data Show More Frequent Selection of Ibalizumab i...